Nancy U. Lin, MD

Dr. Lin serves as associate chief of the Division of Breast Oncology at Dana-Farber. She is the founder and director of the Metastatic Breast Cancer Program and the Program for Patients with Breast Cancer Brain Metastases.

Articles

Advancing Brain Metastases Research and Mentorship in Breast Oncology: With D. Ross Camidge, MD, PhD; Nancy U. Lin, MD

April 30th 2025

Drs Camidge and Lin discussed Dr Lin's work with brain metastases and her role in developing targeted therapies for breast cancer.

Dr Lin on the Safety of T-DXd for HER2+ Breast Cancer With/Without Brain Metastases

November 15th 2024

Nancy U. Lin, MD, discusses the safety data from DESTINY-Breast12 with T-DXd for HER2+ advanced/metastatic breast cancer with or without brain metastases.

Dr Lin on the Importance of the DESTINY-Breast12 Trial for T-DXd Use in HER2+ Breast Cancer With Brain Metastases

October 16th 2024

Nancy U. Lin, MD, discusses the importance of the DESTINY-Breast12 trial of T-DXd in patients with HER2+ breast cancer with vs without brain metastases.

Dr Lin on the Efficacy of T-DXd in HER2+ Advanced Breast Cancer With CNS Metastases

September 14th 2024

Nancy U. Lin, MD, discusses the DESTINY-Breast12 trial of T-DXd in patients with HER2-positive metastatic breast cancer with or without brain metastases.

Dr Lin on the Selection of Systemic Therapy in HER2+ Breast Cancer With Brain Metastases

August 7th 2023

Nancy U. Lin, MD, discusses selecting between systemic vs local therapy for patients with HER2-positive breast cancer displaying central nervous system metastases.

Dr. Lin on the Advantage of Elacestrant in ESR1-Mutated Breast Cancer

June 14th 2022

Nancy U. Lin, MD, discusses the advantage of the oral selective estrogen receptor degrader, elacestrant, in ESR1-mutated breast cancers.

Dr. Lin on Treatment Challenges in HER2+ Breast Cancer and Brain Metastases

October 8th 2020

Nancy U. Lin, MD, discusses the challenges faced in the treatment of patients with HER2-positive breast cancer and brain metastases.

Dr. Lin on Developing Systemic Therapies for Patients with Brain Metastases in HER2+ Breast Cancer

July 9th 2020

Nancy U. Lin, MD, discusses the development of systemic therapies for the treatment of patients with metastatic HER2-positive breast cancer and brain metastases.

Dr. Lin on Updated Findings of HER2CLIMB Study in HER2+ Breast Cancer Brain Mets

May 30th 2020

Nancy U. Lin, MD, discusses updated findings from the phase 2 HER2CLIMB study in patients with HER2-positive metastatic breast cancer with brain metastases.

Dr. Lin on CNS Activity With HER2-Directed TKIs in HER2+ Breast Cancer

April 2nd 2020

Nancy U. Lin, MD, discusses central nervous system activity with HER2-directed TKIs in HER2-positive breast cancer.

x